A world-first chlamydia vaccine is being developed through the A$280m Translational Science Hub, a collaborative venture joining Sanofi with UQ and Griffith University alongside the Queensland Government.
The initiative addresses Australia’s most common sexually transmitted infection, which surged 24% between 2021 and 2023 and is linked to chronic pain and fertility issues. Unlike antibiotics, the vaccine candidate provides protection against primary infection and reinfection.
By connecting local researchers to 600 Sanofi scientists at mRNA Center of Excellence bases in the US and France, this groundbreaking project is set to strengthen Queensland’s capabilities in vaccine manufacturing and preventative healthcare innovation.
A$280m
hub investment
4
vaccine candidates in development
3
global research sites connected
